



RESEARCH ARTICLE

Open Access

The effect of *cassia fistula* emulsion on pediatric functional constipation in comparison with mineral oil: a randomized, clinical trial

Seyyed Ali Mozaffarpur¹, Mohsen Naseri^{2*}, Mohammad Reza Esmailidooki³, Mohammad Kamalinejad⁴ and Ali Bijani³

Abstract

Background: The prevalence of Pediatric Functional Constipation (FC) has been reported between 0.7% to 29.6%. This study was conducted to compare the laxative effect of *cassia fistula* emulsion (CFE) with mineral oil (MO) on FC. *Cassia fistula* is named in Traditional Iranian Medicine (TIM) as "Folus".

Materials and methods: A randomized clinical trial was carried on 81 children (age range: 4–13 years) with FC, according to Rome III criteria in Amirkola Children's Hospital, Babol, Iran. They received CFE or MO randomly for three weeks. CFE was produced according to the order of TIM references. Children were counted as improved when they exited from Rome III criteria of FC. Frequency of defecation, fecal incontinence, retentive posturing, severity of pain, consistency of stool and anal leakage of oily material were compared between the two groups and with baselines. An intent-to-treat analysis was used. Safety of drugs was assessed with the evaluation of clinical adverse effects.

Results: 41 children were assigned randomly to receive CFE and 40 children received MO. After three weeks of medication, 84% of children in CFE group and 50% in MO group ($p = 0.002$) exited from the criteria of FC, so called improved. All measurable criteria improved in both groups. The frequency of defecation in CFE group improved from 1.7 per week (before the study) to 10.6 per week (at the third week) while this parameter differed in MO group from 2 to 6.1 ($p < 0.001$). The severity of pain during defecation and consistency of stool improved significantly better in CFE group than MO group ($p < 0.05$), but there were not any significant differences between the two groups in fecal incontinence and retentive posturing. Anal leakage of oily material occurred as an important complication in MO group while the children in CFE group did not complaint it. Drug's compliances were not significantly different in the two groups. CFE and MO did not cause clinically significant side effects.

Conclusions: CFE was most effective than MO in the 3-week treatment of children with FC.

Keywords: Functional constipation, Children, *Cassia fistula*, Mineral oil, Traditional Iranian Medicine (TIM), Randomized Clinical Trial (RCT)

* Correspondence: naseri@shahed.ac.ir

²Iranian Traditional Medicine Clinical trial Research Center, Shahed University, Tehran, Iran

Full list of author information is available at the end of the article

Introduction

Functional constipation represent the common problems in childhood [1]. Constipation entails more than 3% of visits to pediatricians and 10% to 25% of visits to pediatric gastroenterologists [2,3]. The etiology is usually functional, and only a few cases are diagnosed as suffering an organic pathology [4]. Laxatives drugs mostly include bulking, osmotic, lubricating and stimulant agents [5].

Today, many people seek help from natural based drugs [6] and complementary and alternative medicine [7]. In a literature review of Traditional Iranian Medicine (TIM), we found 134 plants can be used for treatment of constipation [8]. One of the low potent and probably safe and effective plants for the treatment of constipation is *cassia fistula* (called in TIM, "Folus" or "Khlar shanbar"). The different compounds of *cassia fistula* are found in TIM book references [9,10].

Cassia fistula L. (Leguminosae) is cultivated in the tropics like the West Indies, Ceylon, China, Egypt, Amazon, Sri Lanka and many other countries, and is widely used in traditional medicine for children and pregnant women [11] as mild laxative and also as purgative [12]. Its antioxidant [13-16] and hepatoprotective effects [17-20] have been proven. Other therapeutic uses such as immunomodulator, wound healing, antifertility and antiparasitic effects in herbal medicine [11,21-26] and Ayurvedic medicine [13] have been mentioned in literatures. Any serious complication has not been reported in these studies.

Although, *cassia fistula* has cathartic and laxative effect because of the anthraquinone derivatives isolated from the pulp of the its fruits [11,12,27], we did not find any clinical trial research about it. Therefore, we designed a prospective, randomized clinical trial to compare the efficacy, safety, and patient compliance of *cassia fistula* emulsion (CFE) by a formula of TIM [10] vs mineral oil (MO) that is the most commonly used lubricant laxative [5,28] in the treatment of pediatric functional constipation (FC).

Methods and materials

Study design

This study is a clinical trial of 81 functional constipated children, referred to the Pediatric Gastroenterology Department of Amirkola Children's Hospital (Babol, Mazandaran, IRAN), from June to September 2011.

After obtaining informed consent from the parents, the children were divided through a systematic randomization into two parallel therapeutic groups: CFE and MO.

The study was approved by the Ethics Committee of Shahed University and was registered in IRCT (ID: IRCT201107026932N1).

The patients were treated for three weeks. The investigators, the children and their parents were aware of the study group assignment.

Inclusion criteria

Age between 4–13 years old and presence of FC were the inclusion criteria.

Functional constipation was defined by a duration of ≥ 2 months of at least 2 or more of the following characteristics: ≤ 2 defecation in the toilet per week, ≥ 1 episode of fecal incontinence per week, history of retentive posturing or excessive volitional stool retention, history of painful or hard bowel movements, presence of a large fecal mass in the rectum, history of large diameter stools that may obstruct the toilet. These criteria are Paris Consensus on Childhood Constipation Terminology criteria [29] as Rome III criteria of functional constipation [30].

The children with inclusion criteria were visited by the pediatric gastroenterologist to provide complete FC criteria. If history and physical examination could not prove FC, paraclinics like anorectal manometry, thyroid function tests, anti-tTG, and other laboratory tests were performed. If it was confirmed to be FC and the parents were willing the children were entered to the study.

Exclusion criteria

Any symptom of organic constipation in the history, physical examination or paraclinics (such as hypothyroidism, Hirschsprung disease, chronic intestinal pseudo-obstruction and the presence of other chronic diseases that lead to long-term use of drugs and long-term consumption of any drug that can cause constipation.

Drop out criteria

Intolerance of taking drugs comes in the form of nausea, vomiting, severe abdominal pain, allergic protests, incorrect use of medication and the patient's unwillingness to continue treatment

Entering the study

All the children who were referred for treatment of FC were eligible for the study.

If FC was confirmed, the detailed history was taken and recorded in a sheet. In this sheet, the demographic information were recorded. In addition, the average of frequency defecation, retentive posturing, fecal incontinence and large bowel movement per week were questioned.

Also the parents of the children were trained to determine the average severity of pain and the average of consistency of stools defecated in the previous days without the use of any laxative. These scores were measured on the pattern of Visual Analog Scale (VAS) [31-34]. Scores for the severity of pain during defecation were

ranged between 0 (without any pain) and 100 (maximum pain imaginable for parents), and also, scores for average of consistency of stools defecated were in the range between 0 (soft and comfortable) and 100 (maximum consistency imaginable for parents).

The parents learned to compare pain and consistency of stool everyday during the study with these scores. If the situation would have been better, the scores would be less than these scores, and so on.

In physical examination, the presence of an abdominal fecal mass and/or rectal mass and any anal lesion such as fissure, hemorrhoid and fistula was examined.

The treatments started with demystification. If any fecal mass was found, disimpaction was done with normal saline. Regular toilet sittings for 5 minutes after each meal and diet changes were recommended to all the children and then maintenance therapies in two groups were started.

Safety profiles

During every visit and phone call, the parents were questioned with respect to diarrhea, abdominal pain and cramps, anal leakage, exacerbation of constipation, nausea and vomiting, dermatologic complaints, weakness, edema, palpitation or any other adverse effects.

Follow-up

Clinical efficacy and tolerance were assessed using weekly sheets, parents completed every night. They were given three sheets (included seven questions in seven columns) to complete them daily for 3 weeks.

The parents were asked to complete the following: episodes of defecation, fecal incontinence, oily leakage and retentive posturing per day. If the defecation occurred at least once a day, the average of severity of pain and consistency of stool would be written compared with what declared in the beginning of study.

In addition, the parents were asked to explain the acceptance and tolerance of drugs on the bases of our definition, from numbers 1 to 7: taking drug, with willingness, score 1. Taking with no resistance, score 2, and with objections, score 3. Taking with objection and also allurement, score 4. Taking forcefully, score 5. Does not easily take it by force, but tolerate it, score 6. Vomiting, if anyway takes it, score 7.

These concepts and scores were exactly defined and explained to the parents. In every phone call, they were asked to repeat these definitions and talked about them again to achieve their unique meaning. Once every 2–3 days we called up the parents, and if it was necessary and possible spoke with the child. In these calls, they were asked about filling out forms, therapeutic effects and any side effects of the drugs. If there were any serious questions or problems, we visited the child. In average, each child

in the course of study was visited three times and had six phone calls.

At the end of 3 weeks of treatment, the children were visited by the pediatrics gastroenterologist. The filled out sheets were evaluated. If there was a serious mistake in filling out the forms, after explaining it, they were corrected by the parents.

Preparation of CFE

The dried fruits of *cassia fistula* was purchased from local herbal drugs market in Tehran, Iran, and was identified by Herbarium of the Faculty of Pharmacy, Tehran University of Medical Sciences, where the specimens of *cassia fistula* were deposited under the voucher No. PMP-618. The dried fruits were cut into pieces and after isolating the seeds, they were soaked in sterile water. Then with a filter, the aqueous solution of *cassia fistula* was separated from the other parts. The solution was concentrated with heat and under reduced pressure and during concentration (according to TIM reference [11]) sugar and sweet almond oil was added in it, to produce heterogeneous emulsion. Every 1 ml of this emulsion contained 0.1 g of dried pulp of fruits of *cassia fistula*.

Dosage

The children received initially either 1 ml/kg/day MO (manufactured by Hannan co., Brujen, Iran) or 0.1 g/kg body weight daily of CFE.

In Physicians' Desk Reference for Herbal Medicines for *cassia fistula*, the daily dose of 4–8 gram of fruit pulp is recommended [35]. In TIM references, using it up to 20 gram per day is permitted [36].

To obtain an effective dose of CFE, it was used in a step-by-step increasing manner in 3 adults and then 5 children from the dose of 0.05 g/kg (from dried pulp of *cassia fistula*) in a pilot study. After this stage, it seemed that the effective safe dose of emulsion was 0.1 g/kg. So we started to prescribe it and adjust the dose every 3 days by calling up the parents. The parents were provided with guide. The results of the study lines regarding on how to adjust the dosage of medication. In case of diarrhea, the dose was reduced 25%, and if it did not respond well to medication, the dose was increased 25%, all just for one time. MO was prescribed twice daily and CFE in three-separated doses (after each meal).

Primary outcome

The results of the study were: [1] improvement in defecation frequency per week [2] improvement in the episodes of fecal incontinence per week [3] improvement in the episodes of retentive posturing per week [4] improvement in the average of severity of pain of defecation (by VAS) [5] improvement in the average of

consistency of stool defecated (by VAS) [6] patient's drug compliance.

Secondary outcome

Since the duration of therapy in this study was short, a prolonged follow-up was not performed thus, judging about long time recovery was not logical. However, based on criteria Rome III, all the children enrolled this study had at least two of the six criteria. To give a qualitative comparison between the two groups, the frequency of positive criteria of Rome III in children was calculated before medication, first, second and third weeks of the study to compare with one another. During 3 weeks of medication, the patients that had less than 2 of the 6 criteria were called "improved".

Statistical analyses

We hypothesized that CFE would be as effective or better than MO in treating FC. There was not any previous similar study. We estimated that 36 patients were required in each group to be able to detect a difference between the two groups, with 0.05 significance level at 0.80 power.

The data were entered in to SPSS (version 17), and analyzed. Efficacy analyses (improved and not improved) were performed with the intent-to-treat population, defined as all children assigned randomly. Defecation frequency, episodes of fecal incontinence, anal leakage of oil, retentive posturing, severity of pain and consistency of stool were calculated from the available follow-up data. Comparisons were made between the initial data and the follow-up data, between the first, second and

third weeks follow-up data, and within the groups. The statistical analyses included the determination of means and SDs, t test, χ^2 test, ANOVA repeated measures and Fisher's exact test, with significance accepted at the 5% level. The results are expressed as mean \pm SD or percentage.

Result

From June to September 2011 among the 235 patients visited for constipation, 81 patients with FC which included 52(64.2%) boys and 29(35.8%) girls gave their written informed consent and were then randomized to receive the CFE or MO. All patients were followed-up for 3 weeks. The last follow-up visit of the patients treated in both groups was in September 2011. Figure 1 shows a flow chart revealing how the patients in both arms were selected for analysis.

The baseline characteristics of the patients in two treatment groups were similar (Table 1). The age range was between 49 to 132 months with the average of 67.7 (\pm 21.9) months and mean of 60 months. Their mean duration of constipation was 32.5(\pm 24.3) months.

In this randomized, controlled, clinical trial in children with constipation, CFE was more effective than MO for the treatment of FC.

In all our criteria, both drugs were effective. In fecal incontinence and retentive posturing, the results did not have any significant differences between the two groups. However, improvements in defecation frequency, severity of pain and consistency of stool were significantly better in CFE group.




Table 1 Baseline data of the children with functional constipation, in the two treatment groups of cassia fistula emulsion and mineral oil

Variable	CFE group (n = 41)	MO group (n = 40)	p value
Age, months, Mean(±SD)	69.4(±24.3)	65.9(±19.1)	NS
Sex, Male, n (%)	29(70.7%)	23(57.5%)	NS
Weight, Kg(±SD)	21.7 (±7.2)	20.7(±7.8)	NS
Duration of constipation, months, Mean(±SD)	34.2(±25.9)	30.8(±22.8)	NS
Defecation ≤ 2 per week, n (%)	32(78%)	30(75%)	NS
Incontinence, n (%)	31(75.6%)	27(67.5%)	NS
History of previous treatment, n (%)	32(78%)	28(70%)	NS
Fecal impaction, n (%)	23(56.1%)	21(52.5%)	NS
Retentive posturing, n (%)	32(78%)	29(72.5%)	NS

NS: Not Significant.

In addition, even though oily leakage increased as a complication of MO, it did not occur in the CFE group at all. Therefore, lack of this complication is one of the most important advantages of CFE rather than MO.

In qualitative comparison between the two groups, improvement (exit from the criteria of FC) was significantly better in CFE group.

The details of quantitative results are in Figures 2 and 3, and Table 2.

As a qualitative comparison between the two groups, in the 1-week follow-up visit, 43% of the children in the CFE and 39% in the MO group showed improvement. These rates of the 2-week follow-up, were 62% in CFE group and 41% in MO group. After a 3-week follow-up, the improvement rate was significantly better in CFE group, so that 84% in this group exited from the criteria of functional constipation, but improvement in MO

group after 3 weeks was 50% (p = 0.002). The details are in Table 3.


As we had known, anal leakage of oily material was the most common complication of mineral oil [29]. It occurred in 27 of 38 patients (71%) with the average of 10 ± 21 times per week in the first week, in 26 of 37 patients (70%) with the average of 10.8 ± 23 times per week in the second week, and in 22 of 34 patients (64.7%) with the average of 5.5 ± 7.3 times per week in the third week. But this complication was not seen in CFE group. The most common adverse effect in CFE group was diarrhea. Twelve of the 37 patients (32%) in this group by the dose of 1 mg/kg/day had it. All of them recovered by decreasing 25% of the dose. Sputum-like stool (2 times) was seen in one patient of this group. Extra salivation in two patients and headache in one patient of MO group occurred, and recovered after the study and withdraw the drug. Abdominal pain was seen in 3 patients of each group.

In CFE group, no cases withdrew due to adverse effects.

In MO group, four patients did not complete the total duration of medication. A girl (66 months old (m/o)) withdrew after two weeks because of anal leakage of oily material for more than 20 times per day. Two patients withdrew using MO because of lack of response (A boy of 54 m/o after 2 weeks and a girl of 65 m/o after 1 week).

In addition, a girl of 62 m/o withdrew taking MO after 2 weeks because of drug intolerance due to fever and upper respiratory infection.

The average of compliance of drugs in two groups was not significantly different (Table 2). Three patients (59 m/o girl, 51 m/o girl, 71 m/o boy) in CFE group and






Figure 3 A: Severity of pain and **B:** consistency of stool, in the two treatment groups of *cassia fistula* emulsion and mineral oil, in the children with functional constipation, by the score of Visual Analog Scale.

two patients (71 m/o boy, 81 m/o girl) in MO group refused to take them, because of the medicine taste.

Only one patient (52 m/o girl) in CFE group missed to be followed-up. We mentioned her FC clinically. Nevertheless, she did not use the drug at all, and had gone to another center, underwent rectal biopsy, ruled out Hirschsprung disease and began to use poly ethylene glycol (PEG).

Discussion

Cassia fistula has been used more than ten centuries in TIM [9,10,37-39]. The most important phytochemical constituents of *cassia fistula* are potent phenolic

antioxidants such as anthraquinones, flavonoids and flavan-3-ol derivatives [11]. Anthraquinone is responsible for its laxative effect and so it can be categorized as stimulant laxative [5,27].

MO or liquid paraffin that was used in control group, is the most commonly used lubricant laxative [5,28]. It is composed of saturated hydrocarbons obtained from petroleum. MO acts by coating and lubricating stools, reducing colonic absorption of fecal water and facilitating the evacuation of the stools. MO is not chemically active and serious adverse effects are uncommon. Lipoid pneumonia may occur rarely because of MO aspiration [28]. We prefer to choose MO to use in control group because of

Table 2 Outcome data of the children with functional constipation, in two groups of *cassia fistula* emulsion and mineral oil, before and after medication

		Before medication	First week	Second week	Third week
Defecation /w (±SD)	<i>Cassia fistula</i>	1.7(±1.3) ^{NS}	10.7(±6.4) ^c	11(±6) ^c	10.6(±5.7) ^c
	Mineral oil	2(±1.7)	5.8(±4.3)	5.8(±4.3)	6.1(±4.5)
Fecal Incontinence /w (±SD)	<i>Cassia fistula</i>	19.2 (±21.7) ^{NS}	4.9(±10.4) ^{NS}	3.9(±10.1) ^{NS}	3(±9.1) ^{NS}
	Mineral oil	16.6 (±18.7)	6.1(±11.5)	6.3(±11.8)	6.4(±11.1)
Retentive Posturing/w (±SD)	<i>Cassia fistula</i>	17.7 (±19.9) ^{NS}	6.8(±14.5) ^{NS}	6(±12.5) ^{NS}	4.1(±8.9) ^{NS}
	Mineral oil	15.3 (±17.7)	5.9(±9.6)	5.5(±9.9)	4(±8.8)
severity of pain (VAS) (±SD)	<i>Cassia fistula</i>	60.9(±21.5) ^{NS}	19.8(±17.8) ^a	9.5(±11.7) ^c	4.8(±8.5) ^c
	Mineral oil	58.1(±22.6)	31.5(±23.1)	24.8(±21.1)	20.1(±19.9)
consistency of stool (VAS) (±SD)	<i>Cassia fistula</i>	71.9(±11.9) ^{NS}	24.2(±21) ^c	16.2(±16.9) ^c	11.9(±16.8) ^b
	Mineral oil	70(±15)	42.1(±22.8)	32.3(±24.2)	25.4(±22)
Acceptance and Tolerance (±SD)	<i>Cassia fistula</i>	-	2.8(±1.7) ^{NS}	2.5(±1.5) ^{NS}	2.2(±1.5) ^{NS}
	Mineral oil	-	2.7(±5)	2.4(±1.4)	2.4(±1.3)

/w: per week, VAS: Visual Analog Scale, NS: Not Significant, ^ap < 0.05 vs mineral oil, ^bp < 0.01 vs mineral oil, ^cp < 0.001 vs mineral oil.

Table 3 Comparison the effect of treatment in the children with functional constipation, in two groups of *cassia fistula* emulsion and mineral oil, before and after medication

	Number of present criteria/the total criteria of Rome III	BEFORE MEDICATION		FIRST WEEK		SECOND WEEK		THIRD WEEK	
		<i>Cassia fistula</i>	Mineral oil	<i>Cassia fistula</i>	Mineral oil	<i>Cassia fistula</i>	Mineral oil	<i>Cassia fistula</i>	Mineral oil
		(n=41)	(n=40)	(n=37)	(n=38)	(n=37)	(n=37)	(n=37)	(n=34)
Inside the criteria of Rome III	6/6	4	2	0	0	0	0	0	0
	5/6	11	9	0	4	1	2	1	3
(Not improved)	4/6	15	17	4	4	1	4	1	2
	3/6	9	6	4	7	1	8	0	5
	2/6	2	6	13	8	11	8	4	7
Out of criteria	1/6	-	-	8	8	10	9	12	8
(Improved)	0/6	-	-	8	7	13	6	19	9

its effectiveness in studies, long time use in treatment of FC with a good safety profile and fewer side effects and our health center's long time experience on it.

Although constipation is a common chronic problem, there are very few studies with children comparing using different laxatives [40]. Consequently, there is a lack of large well designed placebo – controlled trial in this field [41].

In a comparative study by Urganci N et al., MO was more effective than lactulose in treatment of 40 children with constipation. It responded more rapidly and showed fewer side effects [42]. In another study; Hasan Karimi et al., compared MO with PEG in 103 functional constipated children. The results were better in PEG group, but no significance between the two groups [43].

Martinez-Costa C et al., used MO accompanied with senna in 62 children. Satisfactory results were achieved 1 month later in 32% of the children, 3–6 months later in 71%, and 6–12 months later in 85% [44]. Clinical trial in FC, with herbal source laxative is rare. Senna in this study was effective in 85% of children after 6–12 months accompanied with MO. but in our study, this rate of effectiveness was achieved after 3 weeks of treatment, only with CFE. Senna (*cassia angustifolia*) and *cassia fistula* are both anthranoid laxatives [27] but the prolonged use of senna leads to more prevalent and important complications than *cassia fistula* [35].

Although PEG is now one of the choices of drugs, studies are not absolute. Attar A et al., in 1999 compared a low dose PEG 3350 with lactulose. Their results were not conclusive but they said that low dose PEG 3350 was more effective than lactulose and better tolerated [45]. In 2002, Vera Loening et al., compared PEG with milk of magnesium (MOM) for 49 children. In this study, in the 12-month visit, 61% of children on PEG and 67% on MOM were doing well [46]. In another study, they compared PEG and MOM in 79 children for 12 months. The difference of efficacy was not significant between the two groups, but the acceptance of PEG was

better than MOM [40]. In another study PEG was found to be as effective as lactulose [47]. In 2 randomized trials, PEG with electrolytes was shown to be more effective than lactulose for 91 children over 8 weeks of therapy [48] and for 51 children over a 3-month period [49]. In another study PEG was used for 75 functional constipated children. Constipation was relieved in 85% with short-term (2 months) and in 91% with long-term (11 months) PEG therapy [3].

Although there is not any unique definition and criteria for FC, we used criteria of Rome III as inclusion criteria and for measuring qualitative outcome of the results. Our quantitative outcome measures were well defined by the use of these criteria.

For entering in the study, three steps of explanation, disimpaction and maintenance therapy were performed. Also for disimpactions, we had different choices, but we used enema with normal saline that has been effective in relieving fecal impaction [50].

Close follow-up was one of strength of this study. We called up all the parents every 3 days and talked with them about their children and in case of any changes in their bowel movement habit and other medical problems. Therefore, all of them trust us and because of this good follow-up, we missed only one patient during the study.

In this study, like more other studies in this subject, it was not possible to perform a blind study because these two drugs have different colors, tastes and smell and were administered to children in different ways. Also, because it was the first time *cassia fistula* was used in children, we should be very careful about it and its probable complications.

Another issue in this study was the age of the children entered into the study. Because we were not confident of the safety of drugs, we preferred children older than 4 years for our study. This problem led to a large number of children referred not able to complete the inclusion criteria.

On the other hand, this age of entrance caused most children entered into the study to be visited by pediatricians, before. Most patients have already received medication, but mostly without good result. Some of these patients were refractory to the treatment.

Probably, if the drug would have been used in younger children and as first choice, we could have had better responses and a lower dose of drugs might be needed.

Our baseline characteristics of patients in the two groups were well matched. They were similar to other literatures [40] except in fecal incontinence. In other studies, its frequency differs between 8 to 15.6 episodes per week [40,43,46,48,51], but in our study, it was higher to some extent. It might be because fecal impaction is one of the complications of prolonged constipation, and as our health center is a tertiary and referral one, most of the children entered in to the study had long time history of constipation and taking laxative drugs before.

A short follow-up period is a limitation of our study. One reason for this matter was that, in this study we wanted to demonstrate the effectiveness of CFE as a new drug in the treatment of FC but the Ethics Committee did not permit us to deprive the children from the usual treatment, longer than 3 weeks. This short period of follow-up is current in the first studies in other drugs in this field, for example, this period for PEG was 2 to 4 weeks [45,47]. It was 4 weeks for probiotics [52] and 2 weeks for cellulose [53]. Comparing the effectiveness and possible complications of its long-term use should be investigated in the future studies.

In our study, since the drug dose in patients with CFE was 0.1 g/kg/day, most of our patients had previous medications and might have drug resistance to some extent, so we recommend to the patients to start 0.08 to 0.1 g/ kg/day, based on dried pulp of fruits of *cassia fistula*.

There was no significant difference between the compliance of the two drugs in three weeks. The acceptance of MO in three weeks did not differ significantly, but the acceptance of CFE in the first and second week was less, but in the third week, it was better. It might be because the children found it effective and tolerated its taste.

Conclusion

We offer CFE (*cassia fistula* emulsion) to be used for treatment of FC (pediatric functional constipation), although further researches about its safety should be done. Comparison with other laxatives such as PEG and senna for longer time is recommended.

Abbreviations

FC: Pediatric Functional Constipation; CFE: *Cassia Fistula* Emulsion; MO: Mineral Oil; TIM: Traditional Iranian Medicine; RCT: Randomized Clinical Trial; VAS: Visual Analog Scale; PEG: Poly Ethylene Glycol.

Competing interests

The authors have no competing interests.

Authors' contributions

SAM, designed and performed the research, produced the cassia fistula emulsion and wrote the paper. MN, designed the research and wrote the paper, formulated the emulsion. MRE, designed and performed the research. MK, produced the cassia fistula emulsion. AB, designed the research, analyzed the data. All authors read and approved the final manuscript.

Acknowledgments

This article is derived from a PhD. research project (Thesis) in Shahed University. The authors thank all the families and children who participated in the present study. Also to the staff of Research Centre of Babol University of Medical Sciences to Dr. Evangelina Foronda and Dr. Jila Masrouf for helping us with the manuscript and Dr. Mahdi Yousefi, Mrs. Hoda Shirafkan and Mr. Hasheminejad in helping us to produce the *cassia fistula* emulsion.

Author details

¹Department of Traditional Iranian Medicine, Medical Faculty, Shahed University, Tehran, Iran. ²Iranian Traditional Medicine Clinical trial Research Center, Shahed University, Tehran, Iran. ³Non Communicable Pediatric Diseases Research Center, Babol University of Medical Sciences, Babol, Iran. ⁴Department of Pharmacognosy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Received: 23 June 2012 Accepted: 2 August 2012

Published: 3 December 2012

References

- Loening-Baucke V: Constipation in children. *N Engl J Med* 1998, **339**(16):1155–1156.
- Issenman RM, Hewson S, Pirhonen D, Taylor W, Tirosh A: Are chronic digestive complaints the result of abnormal dietary patterns? Diet and digestive complaints in children at 22 and 40 months of age. *Am J Dis Child* 1987, **141**(6):679–682.
- Loening-Baucke V, Krishna R, Pashankar DS: Polyethylene glycol 3350 without electrolytes for the treatment of functional constipation in infants and toddlers. *J Pediatr Gastroenterol Nutr* 2004, **39**(5):536–539.
- Sauvat F: Severe functional constipation in child: what is the solution? *J Pediatr Gastroenterol Nutr* 2004, **38**(1):10–11.
- Riad Rahhal AU: Motility Disorder, Functional constipation. In *Walker's Pediatric Gastrointestinal Disease fifth edition*. Edited by Ronald E, Kleinman O-JG, Giorgina M-V, et al. Hamilton, Ontario: Bc Decker; 2008:675–682.
- Salari P, Nikfar S, Abdollahi M: A meta-analysis and systematic review on the effect of probiotics in acute diarrhea. *Inflamm Allergy Drug Targets* 2012, **11**(1):3–14.
- van Tilburg MA, Palsson OS, Levy RL, Feld AD, Turner MJ, Drossman DA, et al: Complementary and alternative medicine use and cost in functional bowel disorders: a six month prospective study in a large HMO. *BMC Complement Altern Med* 2008, **8**:46.
- Mozaffarpur M, Kamalinejad MR, Esmaeilidooki M, Yousefi M, Mojahedi M: Khodadust Introduction of natural materia medica, effective in the treatment of constipation, in Traditional Iranian Medicine. *Q J Med Hist* 2012, **3**(9):79–95.
- Avecina, et al: Al-Qanun fi al-Tibb (980–1037 A.D). In *al-din Is*. Edited by Beirut L: Alaalami library; 2005:289–292.
- Aghili SMH: Gharabadin Kabir(10th century AD). In *Vol(1)*. 1st edition. Edited by MM E. Tehran: Tehran University publication; 2009:936–937.
- Bahorun T, Neergheen VS, Aruoma OI: Phytochemical constituents of *Cassia fistula*. *Afr J Food Agric Nutr Dev* 2005, **4**(13):1530–1540.
- Iyengar MA, Pendse GS, Narayana N: Bioassay of *Cassia fistula*. L. (*Aragvadha*). *Planta Med* 1966, **14**(3):289–301.
- Luximon-Ramma A, Bahorun T, Soobrattee MA, Aruoma OI: Antioxidant activities of phenolic, proanthocyanidin, and flavonoid components in extracts of *Cassia fistula*. *J Agric Food Chem* 2002, **50**(18):5042–5047.
- Manonmani G, Bhavapriya V, Kalpana S, Govindasamy S, Apparannantham T: Antioxidant activity of *Cassia fistula* (Linn.) flowers in alloxan induced diabetic rats. *J Ethnopharmacol* 2005, **97**(1):39–42.
- Einstein JW, Mustafa MR, Nishigaki I, Raj Kapoor B, Moh MA: Protective effect of different parts of *Cassia fistula* on human umbilical vein endothelial cells against glycated protein-induced toxicity in vitro. *Methods Find Exp Clin Pharmacol* 2008, **30**(8):599–605.

16. Bhalodia NR, Nariya PB, Acharya R, Shukla V: **Evaluation of in vitro Antioxidant activity of Flowers of Cassia fistula Linn.** *Int J PharmTech Res.* 2011, **3**:589–599.
17. Pradeep K, Raj Mohan CV, Gobianand K, Karthikeyan S: **Protective effect of Cassia fistula Linn. on diethylnitrosamine induced hepatocellular damage and oxidative stress in ethanol pretreated rats.** *Biol Res* 2010, **43**(1):113–125.
18. Bhakta T, Banerjee S, Mandal SC, Maity TK, Saha BP, Pal M: **Hepatoprotective activity of Cassia fistula leaf extract.** *Phytomedicine* 2001, **8**(3):220–224.
19. Bhakta T, Mukherjee PK, Mukherjee K, Banerjee S, Mandal SC, Maity TK, et al: **Evaluation of hepatoprotective activity of Cassia fistula leaf extract.** *J Ethnopharmacol* 1999, **66**(3):277–282.
20. Kalantari H, Jalali M, Jalali A, Mahdavinia M, Salimi A, Juhasz B, et al: **Protective effect of Cassia fistula fruit extract against bromobenzene-induced liver injury in mice.** *Hum Exp Toxicol* 2011, **30**(8):1039–1044.
21. Ali NH, Kazmi SU, Faizi S: **Modulation of humoral immunity by Cassia fistula and amoxy-cassia.** *Pak J Pharm Sci* 2008, **21**(1):21–23.
22. Senthil Kumar M, Sriprya R, Vijaya Raghavan H, Sehgal PK: **Wound healing potential of Cassia fistula on infected albino rat model.** *J Surg Res* 2006, **131**(2):283–289.
23. Yadav R, Jain GC: **Antifertility effect of aqueous extract of seeds of Cassia fistula in female rats.** *Adv Contracept* 1999, **15**(4):293–301.
24. Gupta M, Mazumder UK, Rath N, Mukhopadhyay DK: **Antitumor activity of methanolic extract of Cassia fistula L. seed against Ehrlich ascites carcinoma.** *J Ethnopharmacol* 2000, **72**(1–2):151–156.
25. Sartorelli P, Carvalho CS, Reimao JQ, Ferreira MJ, Tempone AG: **Antiparasitic activity of biochanin A, an isolated isoflavone from fruits of Cassia fistula (Leguminosae).** *Parasitol Res* 2009, **104**(2):311–314.
26. Govindarajan M, Jebanesan A, Pushpanathan T: **Larvicidal and ovicidal activity of Cassia fistula Linn. leaf extract against filarial and malarial vector mosquitoes.** *Parasitol Res* 2008, **102**(2):289–292.
27. van Gorkom BA, de Vries EG, Karrenbeld A, Kleibeuker JH: **Review article: anthranoid laxatives and their potential carcinogenic effects.** *Aliment Pharmacol Ther* 1999, **13**(4):443–452.
28. Bandla HP, Davis SH, Hopkins NE: **Lipoid pneumonia: a silent complication of mineral oil aspiration.** *Pediatrics* 1999, **103**(2):E19.
29. Benninga M, Candy DC, Catto-Smith AG, Clayden G, Loening-Baucke V, Di Lorenzo C, et al: **The Paris Consensus on Childhood Constipation Terminology (PACCT) Group.** *J Pediatr Gastroenterol Nutr* 2005, **40**(3):273–275.
30. Rasquin A, Di Lorenzo C, Forbes D, Guiraldes E, Hyams JS, Staiano A, et al: **Childhood functional gastrointestinal disorders: child/adolescent.** *Gastroenterology* 2006, **130**(5):1527–1537.
31. Philip BK: **Parametric statistics for evaluation of the visual analog scale.** *Anesth Analg* 1990, **71**(6):710.
32. Dexter F, Chestnut DH: **Analysis of statistical tests to compare visual analog scale measurements among groups.** *Anesthesiology* 1995, **82**(4):896–902.
33. Todd KH: **Clinical versus statistical significance in the assessment of pain relief.** *Ann Emerg Med* 1996, **27**(4):439–441.
34. Kelly AM: **The minimum clinically significant difference in visual analogue scale pain score does not differ with severity of pain.** *Emerg Med J* 2001, **18**(3):205–207.
35. Suzanne L: *CBA. PDR for herbal medicine.* Montvale, Bergen County: Medical Economics Company Inc; 2000.
36. Aghili SMH: In *Makhzan- Al' Advieh(19th century AD)*. Edited by Shams MR. Tehran: Tehran University publication; 2008:374.
37. Abolhasan T: In *Elaj al-Atfal(10th century AD)*. Edited by Al-Haji HIA. Qhom: Noor e Vahy; 2011:109.
38. Kermani NIE: *Sharhe Asbab val-Alamat(15th century AD)*. In *first ed.* Edited by Institute ET. Qhom: Jalal al-Din; 2008:92–104.
39. Jorjani SE, et al: *Al-Aghraz al-Tibbia val Mabahesh al-Alaia(1042–1136 AD)*. In *University of Tehran*; 2006:727–729.
40. Loening-Baucke V, Pashankar DS: **A randomized, prospective, comparison study of polyethylene glycol 3350 without electrolytes and milk of magnesia for children with constipation and fecal incontinence.** *Pediatrics* 2006, **118**(2):528–535.
41. van Wering HM, Tabbers MM, Benninga MA: **Are constipation drugs effective and safe to be used in children?: a review of the literature.** *Expert Opin Drug Saf* 2012, **11**(1):71–82.
42. Urganci N, Akyildiz B, Polat TB: **A comparative study: the efficacy of liquid paraffin and lactulose in management of chronic functional constipation.** *Pediatr Int* 2005, **47**(1):15–19.
43. Hasan Karami MK, Parisa Niari: **Polyethylene Glycol versus Paraffin for the Treatment of Childhood Functional Constipation.** *Iran J Pediatr* 2009, **19**(3):255–261.
44. Martinez-Costa C, Palao Ortuno MJ, Alfaro Ponce B, Nunez Gomez F, Martinez-Rodriguez L, Ferre Franch I, et al: **Functional constipation: prospective study and treatment response.** *An Pediatr (Barc)* 2005, **63**(5):418–425.
45. Attar A, Lemann M, Ferguson A, Halphen M, Boutron MC, Flourie B, et al: **Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation.** *Gut* 1999, **44**(2):226–230.
46. Loening-Baucke V: **Polyethylene glycol without electrolytes for children with constipation and encopresis.** *J Pediatr Gastroenterol Nutr* 2002, **34**(4):372–377.
47. Gremse DA, Hixon J, Crutchfield A: **Comparison of polyethylene glycol 3350 and lactulose for treatment of chronic constipation in children.** *Clin Pediatr (Phila)*. 2002, **41**(4):225–229.
48. Voskuil W, de Lorig F, Verwijs W, Hogeman P, Heijmans J, Makel W, et al: **PEG 3350 (Transipeg) versus lactulose in the treatment of childhood functional constipation: a double blind, randomised, controlled, multicentre trial.** *Gut* 2004, **53**(11):1590–1594.
49. Dupont C, Leluyer B, Maamri N, Morali A, Joye JP, Fiorini JM, et al: **Double-blind randomized evaluation of clinical and biological tolerance of polyethylene glycol 4000 versus lactulose in constipated children.** *J Pediatr Gastroenterol Nutr* 2005, **41**(5):625–633.
50. Bautista Casanovas A, Arguelles Martin F, Pena Quintana L, Polanco Allue I, Sanchez Ruiz F, Varea Calderon V: **Guidelines for the treatment of functional constipation.** *An Pediatr (Barc)* 2011, **74**(1):51. e1-7.
51. van Dijk M, Bongers ME, de Vries GJ, Grootenhuis MA, Last BF, Benninga MA: **Behavioral therapy for childhood constipation: a randomized, controlled trial.** *Pediatrics* 2008, **121**(5):e1334–e1341.
52. Bu LN, Chang MH, Ni YH, Chen HL, Cheng CC: **Lactobacillus casei rhamnosus Lcr35 in children with chronic constipation.** *Pediatr Int* 2007, **49**(4):485–490.
53. Lu JP, Huang Y, Zhang Y, Wang XH, Shao CH: **Clinical trial of cellulose in treatment of functional constipation in children.** *Zhongguo Dang Dai Er Ke Za Zhi* 2011, **13**(5):377–380.

doi:10.1186/2008-2231-20-83

Cite this article as: Mozaffarpur et al: The effect of cassia fistula emulsion on pediatric functional constipation in comparison with mineral oil: a randomized, clinical trial. *DARU Journal of Pharmaceutical Sciences* 2012 20:83.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

